论文部分内容阅读
We have shown previously that intraparenchymal infusion of glial cell line- derived neurotrophic factor (GDNF) continuously into the posterior putamen in five Parkinson’ s disease patients is safe and may represent a new treatment option. Here, we report a continuation of this phase I study. After 2 years of continual GDNF infusion, there were no serious clinical side effects and no significant detrimental effects on cognition. Patients showed a 57% and 63% improvement in their off- medication motor and activities of daily living subscores of the Unified Parkinson’ s Disease Rating Scale, respectively, and health- related quality- of- life measures (Parkinson’ s Disease Questionnaire- 39 and Short Form- 36) showed general improvement over time.
We have shown previously that intraparenchymal infusion of glial cell line-derived neurotrophic factor (GDNF) continuously into the posterior putamen in five Parkinson’s disease patients is safe and may represent a new treatment option. Here, we report a continuation of this phase I study. After 2 years of continual GDNF infusion, there were no serious clinical side effects and no significant detrimental effects on cognition. Patients showed a 57% and 63% improvement in their off-service motor and activities of daily living subscores of the Unified Parkinson ’s Disease Rating Scale, respectively, and health-related quality-of-life measures (Parkinson’s Disease Questionnaire- 39 and Short Form- 36) showed general improvement over time.